According to the release, the opening of the laboratory will be celebrated on Monday, December 2, and the company expects the first healthcare samples to arrive at the laboratory during Q1/2025.

With the possible transfer and OTC cross-trading, the company aims, among other things, to improve the liquidity of the stock and to broaden its international shareholder base.

According to the release, Nightingale's Singaporean subsidiary was granted ISO 13485:2016 certification, the final approval needed to begin operations in Singapore. The company says it is now ready to launch its blood testing service in Singapore before the end of the year.

According to the stock exchange release, the pilot announced by Nightingale and Boston Heart in June has been successfully completed. The companies have now signed an agreement to start providing Nightingale's blood test-based Health Check to Boston Heart's customers.

Nightingale has already launched around ten growth starts, mostly with prominent healthcare operators. The strength of demand and speed of progress has surprised us positively in the short term, and we believe the company’s value has taken a clear step forward with the development.